Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis

Leptomeningeal metastases from solid tumors are a rare complication with a very poor prognosis. Here the authors report the efficacy and safety of combined ipilimumab and nivolumab in patients with leptomeningeal carcinomatosis.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Priscilla K. Brastianos, Matthew R. Strickland, Eudocia Quant Lee, Nancy Wang, Justine V. Cohen, Ugonma Chukwueke, Deborah Anne Forst, April Eichler, Beth Overmoyer, Nancy U. Lin, Wendy Y. Chen, Aditya Bardia, Dejan Juric, Ibiayi Dagogo-Jack, Michael D. White, Jorg Dietrich, Naema Nayyar, Albert E. Kim, Christopher Alvarez-Breckenridge, Maura Mahar, Joana L. Mora, Brian V. Nahed, Pamela S. Jones, Helen A. Shih, Elizabeth R. Gerstner, Anita Giobbie-Hurder, Scott L. Carter, Kevin Oh, Daniel P. Cahill, Ryan J. Sullivan
Μορφή:	Άρθρο
Γλώσσα:	English
Έκδοση:	Nature Portfolio 2021-10-01
Σειρά:	Nature Communications
Διαθέσιμο Online:	https://doi.org/10.1038/s41467-021-25859-y

Διαδίκτυο

https://doi.org/10.1038/s41467-021-25859-y